Strand Therapeutics

@Nasdaq helped us in celebrating our Series B with a billboard in the heart of Time Square! Thank you to our friends at Nasdaq for your support on our mission to create cures for patients!

This Friday, our CEO and co-founder, Jacob Becraft will be speaking at the 2026 Milken Institute Future of Health Summit, exploring the future of US biomedical innovation. TIME’s @AliceParkNY will lead the conversation. Fellow panelists include @SecAzar, 24th U.S. Secretary of Health and Human Services; Dave Fredrickson, Executive Vice President at @AstraZeneca; John Halamka, Dwight and Dian Diercks President at the @MayoPlatform and Grace Graham Deputy Commissioner, Policy, Legislation, and International Affairs at the @FDA. See you on November 13 at 1:30 p.m. ET in Washington, DC. Panel info here: milkeninstitute.org/content-… Livestream it on the day: milkeninstitute.org/events/f…

Strand Therapeutics stays committed to making a positive impact for all, both in the lab and at home. We partnered with A Bed for Every Child to provide 10 beds for children in the Greater Boston area, which will help provide many nights of restful sleep and support children’s academic performance and overall health. Shoutout to all the Strands who rolled up their sleeves and built beds!

Yesterday, our CEO and co-founder @DrSynbio sat down with @MTSlive and explained the technology behind STX-003. Until now, genetic medicine has been limited by its own payloads: molecules that are powerful enough to kill cancer are also often toxic to healthy cells. But with this molecular “encryption” technology, Strand is building mRNA medicines that selectively turn on in tumors while sparing healthy cells. Watch the full interview to learn more: youtu.be/uT86Cpy4x0g?t=6356

Strand is bringing two presentations to #SITC26 this week, covering our programs STX-001 and STX-003. Fresh off her late-breaking presentation at ESMO, @ProfGLongMIA of @MelanomaAus will be presenting updated Phase I data on STX-001’s durable, systemic anti-tumor activity. As our first clinical program, STX-001 provided preliminary evidence that a therapy injected directly into a tumor may activate the immune system throughout the body. It helped lay the foundation for STX-003, our flagship clinical program that just dosed its first cohort of patients in ASCENT-1. Trial principal investigator, @MLJohnsonMD2 of @SarahCannonDocs, will present on the design of ASCENT-1, which is evaluating STX-003 as a systemically delivered, programmable self-replicating mRNA engineered to switch on selectively inside tumors. 📅 Friday, November 6 | Phoenix Convention Center 📢 STX-001 oral: 4:55–5:05 pm MT, West Building-300 Level, 301BC 🧬 STX-003 poster: North Building-Lower Level, Exhibition Halls 4-6 You can find more details here: businesswire.com/news/home/2… We’ll see you there.

Strand made an appearance last week in Times Square! Thanks to @Nasdaq for featuring our STX-003 news on the tower. STX-003 is our systemic programmable mRNA therapy, now being administered to patients in the ASCENT-1 clinical trial. The drug is designed to deliver IL-12, a potent cancer-killing immune signal, to tumors throughout the body while staying silent in healthy cells.

Strand has won Best Biotechnology Startup at the 2026 Prix Galien USA Awards, America’s preeminent prize for leading-edge scientific advances. The recognition comes right as we’ve dosed the first patients in ASCENT-1, our trial testing STX-003, an intravenously delivered programmable mRNA therapy to tumors throughout the body. The payload is the potent cancer-killing immune signal IL-12, a molecule with the power to eradicate tumors that’s been sidelined for decades by its toxicity. Controlling where these powerful payloads activate, down to the cell, is what we believe will form the foundation of the next era of medicine. Read the press release from @GalienFdn for more: prnewswire.com/news-releases…

The first patients have been dosed in ASCENT-1, our Phase 1 trial of STX-003, an IV-delivered mRNA therapy designed to bring the potent immune-activating protein IL-12 to tumors throughout the body. It’s our first systemic test of programmable mRNA, and it’s built to solve a problem that’s defined cancer treatment for decades: the drugs powerful enough to kill tumors often damage healthy tissue, too. STX-003 is designed to sidestep that problem by selectively activating where it’s needed. We believe it’s just the start of what the platform could make possible in this era of next-generation delivery. If this works, the same technology could carry other therapeutic proteins, opening the door to a new class of programmable medicines. Our CEO and co-founder @DrSynbio co-founder, President, and Head of R&D @tasuku_kitada take a moment to discuss this milestone and how this trial is a test of a fundamentally new approach to treating disease. 🧬 Learn more: businesswire.com/news/home/2…

Today at 2:00 pm ET, our CEO and co-founder @DrSynbio takes the virtual stage for a @biospace panel on U.S.-China biotech competition, what it means for where early drug development happens, and the policy decisions shaping what’s next. Catch it live this afternoon: biospace.com/events/register…

This past summer, Strands have shown up both in the lab and on the field. We would like to extend a congratulations to the members of our intramural sports teams on their dedication and highly successful seasons!

Celebrating our CEO and co-founder @DrSynbio on being named to this year's @biospace 40 Under 40 cohort. Jake continues to lead Strand with determination and tenacity as we work to improve treatment options for patients with cancer and other life-threatening diseases. Congrats, Jake, and to all of this year's honorees! See the full list here: biospace.com/business/biospa…

Strand Therapeutics is gearing up for Fall! To celebrate the Fall equinox, Strands got creative and painted mini pumpkins!🍂🍁

Last month, we welcomed about 20 PhD students and postdocs from the @thebiotechclub to our Boston office for an afternoon of touring our space and hearing from our team – including a talk and Q&A with co-founder, President, and Head of R&D @tasuku_kitada, alongside scientists from our program management and translational medicine groups. This week, Tasuku’s conversation with Harvard Biotech Club’s The Pulse podcast is live and he talks through Strand's programmable mRNA platform, his path from biotech investing back into R&D, and what could be next for oncology and autoimmune disease. Listen to the full conversation: hbcpulse.substack.com/p/tasu…

Excited to share that Strand Therapeutics has once again been nominated in the Best Startup category for the 2026 Prix Galien USA Awards by @GalienFdn recognizing innovation advancing global health. Congratulations to our fellow nominees, and we look forward to celebrating the advancement of science together this fall. More info here: prnewswire.com/news-releases…

Last week, our co-founder and CEO @DrSynbio joined Endpoints News and Roivant Sciences CEO @gline for a live debate on China's impact on biotech. Jake made the case that while protectionism is an important consideration, we have to stay focused on acceleration. He pointed to Australia's clinical trial capacity running at four times the U.S. rate despite having a tenth of the population. This isn’t just a sign of how much room there is to move faster here. The gap is felt by patients, too. 86% of non-metro U.S. hospitals don't run clinical trials, meaning many patients have to leave home to access experimental treatments. Catch the full conversation via Endpoints Post-Hoc: youtube.com/watch?v=EXph7rim…

Last month, our Spring Co-ops celebrated the end of their cycle by presenting their hard work to our team! Strand is incredibly proud to have been a part of their journeys, and we wish them the best of luck in their future endeavors!

Strand CEO and co-founder @DrSynbio spoke about why quality beats speed in the China biotech debate and the importance of building fundamentally revolutionary medicines that are genuinely hard to replicate. Read his take in In Vivo, a @Citeline publication, as senior reporter @davidwild77 looks at how Western biotechs are defining their strategy against China's biotech surge: insights.citeline.com/in-viv…